Fulvestrant in advanced male breast cancer

Haba, Juan de la; Quintela, I; Cortijo, G Pulido; Berciano‐Guerrero, Miguel‐Ángel; Aranda, Enrique

doi:10.1093/annonc/mdp413

Cited by 15 publications

(3 citation statements)

References 8 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, tamoxifen is the cornerstone of hormonal treatment for male breast cancer, although the definition of this standard results from relatively small retrospective studies or is extrapolated from trials conducting in female breast cancer patients (Kantarjian et al , 1983; White et al , 2011). The use of fulvestrant in male breast cancer was proposed owing to their success in females, with a few published case series showing promising results in men as well (de la Haba Rodríguez et al , 2009; Masci et al , 2011; Zagouri et al , 2013). …”

Section: Discussionmentioning

confidence: 99%

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series

et al. 2013

View full text Add to dashboard Cite

Background:Data regarding the safety and effectiveness of aromatase inhibitors (AIs) as monotherapy or combined with gonadotropin-releasing hormone (GnRH) analogue in male breast cancer are scarce.Methods:In this retrospective chart review, cases of male breast cancer patients treated with AIs with or without a GnRH analogue were evaluated.Results:Twenty-three men were included into this case series. Aromatase inhibitors in combination with or without a GnRH analogue were given as first-line therapy in 60.9% and as second-line therapy in 39.1% of patients, respectively. All patients had visceral metastases, whereas in five of them bone lesions coexisted. In all cases AIs were tolerated well, and no case of grade 3 and 4 adverse events was reported. A partial response was observed in 26.1% of patients and stable disease in 56.5%. Median overall survival (OS) was 39 months and median progression-free survival (PFS) was 13 months. Regarding OS and PFS, no significant effects of GnRH analogue co-administration or type of AI were noted.Conclusion:Our study shows that AIs with or without GnRH analogues may represent an effective and safe treatment option for hormone-receptor positive, pretreated, metastatic, male breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In a series of 15 cases of patients with metastatic or locally advanced male BC who received aromatase inhibitors, 2 patients (13%) had a complete response, 4 patients (27%) had a partial response, 2 patients (13%) had stable disease, and 7 patients (47%) had progressive disease; the median progressionfree survival (PFS) was 4.4 months [67]. A limited number of case studies of the selective estrogen receptor degrader fulvestrant in men with metastatic BC have shown extended partial responses or stable disease [68][69][70]. Combinations of endocrine and targeted agents, such as mTOR and CDK inhibitors, can be used in metastatic male BC patients, as the same indications are used for their female counterparts.…”

Section: Treatment Options For Metastatic Male Breast Cancermentioning

confidence: 99%

Male breast cancer: a disease distinct from female breast cancer

Gucalp

Traina

Eisner

et al. 2018

Breast Cancer Res Treat

270

195

View full text Add to dashboard Cite

show abstract

“…In the Chinese Clinical Oncology Society, several successful cases of the treatment of male breast cancer patients have been reported. Because >90% of male breast cancers express ER, 62 hormone therapy is frequently used, and letrozole is one frequently used therapy.…”

Section: Letrozole In People’s Republic Of Chinamentioning

confidence: 99%

Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective

2016

OTT

View full text Add to dashboard Cite

The incidence rate of breast cancers in People’s Republic of China has increased in the last decade, and many cases are responsive to hormone therapies. The third-generation aromatase inhibitor letrozole inhibits estrogen production, and is more efficacious than the estrogen receptor inhibitor tamoxifen. In recent years, letrozole has been widely used to treat postmenopausal breast cancers in People’s Republic of China. Also, metastatic, premenopausal, and male breast cancers have been effectively treated by a combination of letrozole with cytotoxic, radiation, or other therapies. In this review, we provide a perspective and summary of recent advances in the use of letrozole for breast cancer in Chinese patients.

show abstract

Fulvestrant in advanced male breast cancer

Cited by 15 publications

References 8 publications

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series

Male breast cancer: a disease distinct from female breast cancer

Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective

Contact Info

Product

Resources

About